The historical roots of hantavirus research trace back to the Korean War in the early 1950s, when thousands of United Nations soldiers developed a severe febrile illness later identified as Korean hemorrhagic fever. The causative agent, Hantaan virus, was not isolated until 1978 near the Hantan River in South Korea, giving rise to the name hantavirus. Since that discovery, numerous hantavirus species have been identified worldwide, each tightly associated with a specific rodent or small mammal reservoir. Today, hantaviruses are classified within the order Bunyavirales and the family Hantaviridae, a taxonomic revision that reflects their unique genetic and biological characteristics compared with other bunyaviruses. The genus Orthohantavirus contains the majority of species pathogenic to humans, including Hantaan virus, Seoul virus, Puumala virus, Dobrava-Belgrade virus, Sin Nombre virus, and Andes virus.

Structurally, hantaviruses form spherical virions measuring approximately 80 to 120 nanometers in diameter, enclosed by a lipid envelope studded with glycoprotein spikes that mediate host cell recognition, attachment, and membrane fusion. The genome consists of three segments of negative-sense single-stranded RNA designated large, medium, and small. The large segment encodes the RNA-dependent RNA polymerase responsible for transcription and replication, the medium segment encodes the precursor of the envelope glycoproteins Gn and Gc, and the small segment encodes the nucleocapsid protein that binds and protects viral RNA. Beyond its structural role, the nucleocapsid protein contributes to immune evasion by interfering with host innate immune responses. Critically, the segmented genome permits genetic reassortment when multiple strains co-infect the same host cell, a mechanism that enhances viral diversity and can generate novel strains with altered virulence and host range.

The replication cycle of hantaviruses is entirely cytoplasmic, distinguishing them from many other RNA viruses that involve nuclear stages. Viral entry is initiated through interactions between surface glycoproteins and host cell receptors, including β3 integrins, β1 integrins, decay-accelerating factor, and protocadherin-1, the latter identified as a particularly critical entry receptor for New World hantaviruses such as Andes virus, Sin Nombre virus, and Laguna Negra virus. Following receptor engagement, virions enter cells predominantly through clathrin-mediated endocytosis, and endosomal acidification triggers conformational changes that facilitate membrane fusion. The viral polymerase employs a cap-snatching mechanism, cleaving short capped fragments from host messenger RNAs to prime viral mRNA synthesis, a strategy that ensures efficient translation while contributing to host protein synthesis shutoff and immune evasion. Virion assembly occurs primarily at the Golgi apparatus before mature particles are released via the secretory pathway.

Epidemiologically, hantaviruses impose two distinct clinical syndromes shaped by geography and viral species. Hemorrhagic fever with renal syndrome, caused by Old World viruses such as Hantaan, Seoul, Puumala, and Dobrava-Belgrade, predominates in Europe and Asia and follows a classically five-phase course encompassing febrile, hypotensive, oliguric, polyuric, and convalescent stages, with mortality ranging from less than 1 percent in mild Puumala infections to roughly 15 percent in severe Dobrava-Belgrade cases. Hantavirus cardiopulmonary syndrome, driven by New World viruses in the Americas, presents with fulminant respiratory compromise, pulmonary edema, and cardiogenic shock, with case-fatality rates reaching 40 to 50 percent despite intensive supportive care. China bears the highest global burden of hemorrhagic fever with renal syndrome, while Puumala virus drives cyclical outbreaks across Northern and Central Europe tied to fluctuations in bank vole populations. In the Americas, Andes virus stands apart as the only hantavirus with well-documented person-to-person transmission, primarily among household members, sexual partners, and caregivers during the prodromal phase when viral loads are high but symptoms remain nonspecific.

Transmission to humans occurs overwhelmingly through inhalation of aerosolized viral particles from contaminated rodent urine, feces, and saliva, particularly in enclosed or poorly ventilated spaces. Secondary routes include contact with contaminated fomites, rodent bites, and consumption of contaminated food or water. High-risk groups encompass farmers, forestry workers, military personnel, laboratory workers, and outdoor enthusiasts. Rodent population dynamics, governed by climatic fluctuations such as El Niño Southern Oscillation events, deforestation, agricultural expansion, and urban encroachment into wildlife habitats, strongly modulate spillover risk. Despite public concern, the review emphasizes that hantaviruses lack efficient airborne transmission comparable to influenza or SARS-CoV-2, and human-to-human spread remains rare and largely restricted to Andes virus, a constraint that limits widespread global dissemination even as localized outbreaks with serious consequences persist.

Pathogenically, hantavirus disease is defined by profound vascular permeability resulting from endothelial dysfunction rather than direct cytopathic injury. The viruses preferentially infect vascular endothelial cells and persist without causing overt cell lysis, meaning that host immune responses, not viral-mediated death, drive tissue injury. Pattern-recognition receptors including Toll-like receptors 3 and 7 and cytosolic sensors RIG-I and MDA5 initiate type I interferon signaling, yet many hantaviruses encode mechanisms to blunt this response, delaying antiviral defenses. Subsequent adaptive immunity, characterized by cytotoxic T lymphocyte expansion and neutralizing antibodies against the Gn and Gc glycoproteins, can clear infection, but dysregulated or excessive responses generate a cytokine storm phenotype that disrupts endothelial barrier integrity. This delicate balance between viral control and immunopathology shapes disease severity and informs therapeutic strategies aimed at restoring antiviral control while tempering hyperinflammation.

Diagnosis relies on a combination of clinical suspicion, exposure history, and laboratory confirmation, with serological assays detecting virus-specific IgM and IgG antibodies remaining the most widely used approach, complemented by reverse transcription polymerase chain reaction for early viral RNA detection and genome sequencing for strain identification. However, nonspecific early symptoms, a narrow window of viremia, serological cross-reactivity among related species, and limited access to molecular diagnostics in resource-constrained settings continue to impede accurate case recognition, particularly in Africa and many low- and middle-income countries. Treatment remains fundamentally supportive, encompassing oxygen supplementation, mechanical ventilation, extracorporeal membrane oxygenation, hemodynamic stabilization, and renal replacement therapy as needed. Ribavirin has shown partial efficacy against certain Old World hantaviruses when administered early, while favipiravir, monoclonal antibodies, and nanotechnology-based delivery platforms represent promising but still investigational avenues. No universally approved vaccine exists; licensed inactivated formulations are restricted to China and South Korea for selected Old World strains, and next-generation platforms including DNA, mRNA, recombinant viral vector, and virus-like particle vaccines are under development to achieve broader cross-protection.

The review operationalizes a One Health framework into concrete prevention and control actions, calling for integrated human-animal-environment surveillance, targeted rodent reservoir monitoring, environmental sampling, and formal intersectoral coordination mechanisms. Primary prevention centers on environmental sanitation, rodent-proofing, proper ventilation of enclosed spaces before cleaning, wet-cleaning methods that minimize aerosol generation, and personal protective equipment for occupationally exposed individuals. Community education campaigns play a critical role in improving risk perception and encouraging early medical consultation after high-risk exposures. Genomic surveillance, combined with climate modeling and ecological forecasting, enables more precise outbreak reconstruction and proactive preparedness, while artificial intelligence-assisted prediction models may further enhance the integration of ecological, climatic, and epidemiological data.

Looking ahead, the author identifies persistent controversies and knowledge gaps, including the determinants of reservoir competence, the sensitivity of current surveillance systems, and the limits of predictive models, alongside unresolved questions about the biological basis of Andes virus transmissibility and whether other hantavirus species harbor undetected human-to-human potential. Although a COVID-19-like global pandemic caused by hantaviruses currently appears unlikely given their transmission dynamics, the review concludes that increasing ecological disruption and global connectivity demand sustained interdisciplinary collaboration among virologists, epidemiologists, ecologists, clinicians, and public health authorities. Strengthening early warning systems, expanding genomic surveillance, developing pan-hantavirus vaccines and broad-spectrum antivirals, and formalizing One Health coordination mechanisms are framed as essential pillars for preventing future high-consequence hantavirus events in an era of accelerating environmental change.

Subject of Research: Hantavirus zoonotic spillover risk, molecular virology, and One Health preparedness

Article Title: Hantaviruses at an inflection point: scientific evidence, spillover risk, and One Health approach

Article References: Zatla, I. (2026). Hantaviruses at an inflection point: scientific evidence, spillover risk, and One Health approach. Frontiers in Virology, 6, Article 1883348. https://doi.org/10.3389/fviro.2026.1883348

Image Credits: AI Generated

DOI: 10.3389/fviro.2026.1883348

Keywords: hantavirus, zoonosis, rodent reservoirs, Andes virus, One Health, hemorrhagic fever with renal syndrome, hantavirus cardiopulmonary syndrome, spillover, genomic surveillance, vaccine development, antiviral therapy, public health preparedness

The outbreak first came to the attention of the World Health Organization on May 2, 2026, when passengers aboard the MV Hondius, which carried 147 crew members and passengers from 23 countries, presented with fever and gastrointestinal symptoms that rapidly progressed to pneumonia, shock, and acute respiratory distress syndrome. Laboratory confirmation of Andes virus infection by polymerase chain reaction followed between May 4 and May 6. By July 2, 2026, 13 cases had been identified on the vessel, 12 confirmed and one probable, and three patients had died, yielding a case fatality ratio of 23 percent. Epidemiologists hypothesize that an initial case acquired the infection from a rodent before boarding, with subsequent human-to-human transmission occurring during the prolonged, close contact that confined shipboard conditions inevitably produce.

Andes virus, formally Orthohantavirus andesense, occupies a unique position among hantaviruses. While hantaviruses are typically transmitted from rodents to humans through contact with urine, feces, or saliva, and humans are generally considered dead-end hosts, Andes virus is the only hantavirus documented to spread efficiently between people. First identified in Argentina in 1995, the virus has an incubation period ranging from 7 to 42 days, with a median of 18 days, and viral RNA has been detected in blood, respiratory secretions, urine, and semen. Transmission can occur through mucosal or respiratory exposure to infectious respiratory particles, although the virus is not classified as highly airborne. Case fatality ratios have reached 50 percent in some settings, and the virus has a documented history of super-spreading events, most dramatically during Argentina’s 2018 to 2019 outbreak, when transmission at a large social gathering linked to three super-spreaders produced the largest Andes virus outbreak recorded to date, with a case fatality ratio of approximately 32 percent.

Genomic sequencing of viruses isolated from the MV Hondius passengers detected no new lineages, and the circulating strain closely resembled Andes virus lineages previously identified in Argentina and Chile. The outbreak’s reproductive number was estimated at 0.7, considerably lower than the median reproductive numbers of 2.12 and 0.96 observed before and after infection control measures during the Argentine outbreak. Because the incubation period can extend to six weeks, disembarked passengers were asked to quarantine for 42 days, a duration that health authorities calculate provides a 96 percent probability of safe release. The episode has nonetheless highlighted the vulnerability of international transportation systems, where restricted spaces, overcrowding, inadequate ventilation, and limited access to intensive care can amplify transmission. Experts now recommend screening passengers boarding from hantavirus-endemic regions, controlling rodents on ships and in harbors, and establishing approved protocols for managing infectious diseases in international waters.

The pathogenesis of Andes virus infection centers on endothelial dysfunction. Hantaviruses target endothelial cells, producing enhanced microvascular permeability in the principal target organs: the lungs in hantavirus cardiopulmonary syndrome, which predominates in the Americas, and the kidneys in hemorrhagic fever with renal syndrome, which prevails in Europe and Asia. Immune-mediated mechanisms play a pivotal role. CD8-positive T cell activation has been documented during acute phases of both syndromes, immunoblasts circulate in patients experiencing shock or pulmonary edema, and fatal cases show high densities of cytokine-releasing cells in lung tissue. Elevated levels of tumor necrosis factor alpha can drive capillary leakage, pulmonary edema, and shock, while high interleukin 2 levels increase vascular permeability. Hantavirus cardiopulmonary syndrome unfolds in three phases: a prodromal phase of non-specific flu-like symptoms, a cardiopulmonary phase marked by pulmonary capillary leak and hemodynamic compromise that can culminate in cardiogenic shock, and a convalescent recovery phase.

Early diagnosis is critical because no specific antiviral agent exists. Reverse transcription polymerase chain reaction can detect viral RNA in whole blood during the asymptomatic and prodromal phases, and serological confirmation relies on IgM and IgG assays performed with chemiluminescence immunoassay technology. IgM antibodies appear at symptom onset, rise within a week, and clear after one to three months, whereas IgG antibodies emerge three to seven days after symptoms begin and persist for years, making them unsuitable for early diagnosis. Notably, some polymerase chain reaction-positive cases have been entirely asymptomatic, and viremia can precede symptoms. Differential diagnoses during the prodromal phase include influenza, COVID-19, viral and atypical pneumonias, yellow fever, dengue, leptospirosis, endocarditis with pulmonary edema, sepsis with acute respiratory distress syndrome, and arenavirus infections, underscoring the diagnostic challenge clinicians face.

Clinically, initial symptoms of hantavirus cardiopulmonary syndrome typically emerge one to eight weeks after exposure and include chills, fever, gastrointestinal upset, nausea, vomiting, diarrhea, headache, dizziness, and myalgia, before sudden progression to respiratory distress, hypotension, and shock. A recent systematic review and meta-analysis identified prognostic factors for severe outcomes, including female sex, age over 18, rural residence, pulmonary infiltrates on chest radiographs, underlying disease with elevated serum creatinine and hematocrit, and signs of bleeding. For patients with severe disease, extracorporeal membrane oxygenation can be life-saving; in experienced centers in the United States, Argentina, and Chile, ECMO-supported survival has ranged from approximately 60 to 75 percent. Timely administration of antipyretics, vasopressors, fluid therapy, mechanical ventilation, and renal replacement therapy, tailored to infection severity and organ involvement, remains the foundation of care.

On the pharmacological front, favipiravir is the most studied antiviral under consideration for Andes virus, though most safety and efficacy data derive from its use against other viral infections. A recently published case report described a 69-year-old man, diagnosed through screening after repatriation from the cruise ship, who received a combination of oral favipiravir, subcutaneous icatibant, intravenous then oral ribavirin, and oral baricitinib over a proposed 10-day course. The patient developed hypoxemia, hyponatremia, thrombocytopenia, and bilateral interstitial infiltrates roughly 24 hours after diagnosis, but recovered clinically, radiologically, and laboratory-wise from day two without progressing to shock or requiring vasopressors or invasive ventilation. Ribavirin and favipiravir were discontinued on days five and nine, respectively, after recurrent diarrhea and hyponatremia. The authors caution that a single favorable outcome cannot establish efficacy, and larger studies are required. Icatibant, a selective bradykinin B2 receptor antagonist, is hypothesized to alleviate bradykinin-driven vascular leakage, while the interleukin 6 receptor antagonist tocilizumab showed striking signals in a MEURI case series: five of five untreated ICU patients with Andes virus cardiopulmonary syndrome died, compared with four of five survivors among those receiving a single 8 mg/kg intravenous dose within 24 hours of admission. By contrast, a double-blind randomized trial in Chile found that high-dose intravenous methylprednisolone provided no significant clinical benefit in hantavirus cardiopulmonary syndrome, and monoclonal antibodies, molnupiravir, and baloxavir remain at earlier stages of investigation.

Vaccine development remains an empty pipeline in Western nations, with no approved hantavirus vaccine in the United States or Europe, although the inactivated Hantavax vaccine is used in Korea and China. A DNA vaccine targeting the Andes virus glycoprotein has completed Phase I testing: in a randomized controlled trial of 48 healthy adults, needle-free administration of 2 mg or 4 mg doses in three- or four-dose schedules was generally well tolerated, induced neutralizing antibodies, and achieved seropositivity rates of 67 to 90 percent by day 337, with only mild to moderate adverse events. Viral vector vaccines based on vesicular stomatitis virus and mRNA vaccines using both uridine and N1-methylpseudouridine platforms are in preclinical development, and recombinant human monoclonal antibodies JL16 and MIB22 have provided high levels of post-exposure protection in animal models by neutralizing viral glycoproteins. The review’s authors conclude that while the public health risk from the current outbreak remains low, the MV Hondius episode demonstrates that Andes virus could become a broader global concern, and they urge accelerated development of specific antivirals and vaccines, particularly mRNA platforms, alongside sustained vigilance in isolation, physical distancing, rodent control, and global cooperation to manage unpredictable outbreaks in the years ahead.

Subject of Research: Epidemiology, pathogenesis, and pharmacological management of the 2026 Andes virus outbreak linked to a cruise ship

Article Title: Incidence, pathogenesis, clinical manifestations, and pharmacological management of the 2026 Andes virus outbreak

Article References: Ghasemiyeh, P., & Mohammadi-Samani, S. (2026). Incidence, pathogenesis, clinical manifestations, and pharmacological management of the 2026 Andes virus outbreak. Virology Journal, 23(1), Article 208. https://doi.org/10.1186/s12985-026-03298-9

Image Credits: AI Generated

DOI: 10.1186/s12985-026-03298-9

Keywords: Andes virus, hantavirus, hantavirus cardiopulmonary syndrome, MV Hondius, cruise ship outbreak, human-to-human transmission, favipiravir, tocilizumab, ECMO, DNA vaccine, mRNA vaccine, public health

Andes virus is a New World orthohantavirus carried primarily by the long-tailed pygmy rice rat, and it is unusual among hantaviruses in its capacity for person-to-person transmission, a feature documented in household clusters in Chile and in so-called super-spreading events in Argentina. Infection produces hantavirus cardiopulmonary syndrome, a biphasic illness that begins with a prodrome of fever, myalgia and gastrointestinal symptoms before progressing abruptly to cardiopulmonary compromise. The hallmark pathophysiology is a dramatic increase in microvascular permeability driven by infection of endothelial cells, leading to non-cardiogenic pulmonary edema, hypoxemia and myocardial depression. Unlike many viral hemorrhagic fevers, the dominant clinical problem is the lung and heart rather than bleeding, and the window from first respiratory symptoms to critical illness can be a matter of hours.

The new study was motivated in part by renewed international attention to the disease after a reported case-outbreak of hantavirus cardiopulmonary syndrome on a cruise ship, an event that highlighted how rarely appreciated zoonoses can surface in unexpected settings and how gaps remain in global preparedness. The research team, led by Gabriela Meza-Fuentes and René López of Universidad del Desarrollo and Clínica Alemana in Santiago, used Chile’s Diagnosis-Related Groups database to identify patients admitted with the syndrome over a six-year window, a period spanning the pre-pandemic baseline, the COVID-19 pandemic itself and the post-pandemic recovery.

The cohort comprised 215 patients with laboratory-confirmed hantavirus cardiopulmonary syndrome, of whom 69.3 percent were male and 87 percent were adults. Respiratory support was required by 148 patients. Within this group, the escalation of organ support was striking: 14.2 percent received non-invasive ventilation, 36.5 percent were managed with invasive mechanical ventilation, and 49.3 percent ultimately needed extracorporeal membrane oxygenation. In other words, among patients who could not maintain oxygenation on their own, half progressed to the most invasive form of life support available, reflecting the fulminant nature of the cardiopulmonary phase and the limited ability of conventional ventilation to compensate for a lung flooded with protein-rich edema fluid.

Outcomes tracked this intensity of care. The median hospital length of stay was eight days, with an interquartile range of three to fifteen days, and overall in-hospital mortality was 20.5 percent. Case fatality rose steeply with the level of organ support, reaching 29.6 percent among patients on invasive mechanical ventilation and 32.9 percent among those supported with ECMO. These figures are consistent with the historical literature, in which venoarterial or venovenous extracorporeal support has been credited with rescuing a substantial fraction of patients who would otherwise have died of refractory hypoxemia and shock. Early reports from the late 1990s in North America, and subsequent Chilean and Argentine series, established ECMO as the single most effective rescue therapy for the syndrome, and the current cohort confirms that this dependence has not diminished in contemporary practice.

Perhaps the most consequential finding of the temporal analysis concerns the pandemic period. After adjusting for covariates, the COVID-19 pandemic years were independently associated with higher in-hospital mortality from hantavirus cardiopulmonary syndrome, with an adjusted odds ratio of 2.73 and a p-value of 0.045. This echoes observations from other settings in which critically ill patients without COVID-19 fared worse during pandemic surges, a phenomenon attributed to strained intensive care capacity, deferred admissions, exhausted staff and reduced availability of highly specialized resources such as ECMO referral. For a disease in which survival hinges on timely transfer to a center capable of extracorporeal support, pandemic-era system stress could plausibly have delayed the escalation of care precisely when patients were deteriorating fastest.

The pathophysiological substrate of the disease helps explain why it remains so refractory to treatment. Hantaviruses enter host cells through protocadherin-1 and related receptors, infecting pulmonary endothelium and, as recent biomarker work suggests, the alveolar epithelium as well. The resulting vascular leak is amplified by sensitization to vascular endothelial growth factor, while the myocardium fails in a manner resembling a viral cardiomyopathy. Because the injury is primarily immune-mediated and permeability-driven rather than cytopathic destruction, antiviral drugs and corticosteroids have both failed to show clear benefit in randomized trials, including a double-blind Chilean trial of high-dose methylprednisolone and a multicenter trial of human immune plasma. Supportive critical care, fluid-restricted hemodynamic management and extracorporeal rescue therefore remain the pillars of therapy, and mortality has changed little over two decades.

The authors note that their dataset, derived from a national administrative database, captures the real-world distribution of organ support across both public and private hospitals, rather than the referral-biased case series that have dominated the literature. This matters for planning: hantavirus cardiopulmonary syndrome is seasonal, tied to rodent population dynamics and human exposure in rural central and southern Chile, and clusters of severe cases can rapidly consume regional ECMO capacity. With person-to-person transmission documented and the virus endemic across a broad swathe of Patagonia on both sides of the Andes, the study provides a contemporary benchmark against which emerging interventions can be judged. Several candidate therapeutics, including monoclonal antibodies directed at the viral envelope, are in preclinical development, and any future trial will need outcome data of exactly this kind to size studies and define endpoints.

For clinicians, the message is sobering but practical. Hantavirus cardiopulmonary syndrome in the modern era still kills one in five hospitalized patients, and among those who need respiratory support, the majority will require invasive ventilation and nearly half will need extracorporeal life support. Early recognition of the cardiopulmonary phase, immediate referral to centers with ECMO capability and vigilant preservation of critical care capacity during health system crises are the interventions most likely to move these numbers. The finding that pandemic-era mortality nearly tripled serves as a warning that even a well-organized national response can be vulnerable when intensive care resources are diverted, and it underscores the preparedness gap that recent commentaries on rare zoonoses have emphasized for Andes virus and its relatives.

The study was supported by Chile’s National Agency for Research and Development, and its dataset is publicly available through the Chilean National Health Fund’s open data platform. As climate change, land-use change and human encroachment on rodent habitats continue to reshape the ecology of zoonotic spillover in South America, national cohorts of this kind will remain essential for tracking whether the critical care burden of Andes virus infection is shifting, and whether decades of experience with extracorporeal support are finally being translated into falling mortality.

Subject of Research: Critical care burden, organ support use and outcomes of Andes virus-associated hantavirus cardiopulmonary syndrome in Chile.

Article Title: Temporal trends in critical care burden and outcomes of Andes virus-associated hantavirus cardiopulmonary syndrome: a national Chilean cohort

Article References: Meza-Fuentes, G., Delgado, I., Vial, P. A., Godoy-Faúndez, A., Rivera, D., Bernal, Y., Graf, J., & López, R. (2026). Temporal trends in critical care burden and outcomes of Andes virus-associated hantavirus cardiopulmonary syndrome: a national Chilean cohort. Intensive Care Medicine. https://doi.org/10.1007/s00134-026-08599-9

Image Credits: AI Generated

DOI: 10.1007/s00134-026-08599-9

Keywords: Andes virus, hantavirus cardiopulmonary syndrome, critical care, ECMO, mechanical ventilation, in-hospital mortality, Chile, zoonosis, COVID-19 pandemic, intensive care, respiratory support, epidemiology

Hantaviruses have been predominantly identified in the Americas, Europe, and Asia, with an intriguing dual clinical manifestation largely dictated by geographic viral strain variation. In the Americas, notably, the hantavirus cardiopulmonary syndrome (HCPS) represents a severe respiratory illness characterized by rapid progression and high fatality if untreated. Contrarily, the old-world hantavirus strains tend to induce hemorrhagic fever with renal syndrome (HFRS), a condition that affects vascular permeability and renal function with profound clinical consequences. The incubation period for these syndromes generally spans two to four weeks, during which infected individuals experience nonspecific symptoms such as fever, headaches, myalgia, and gastrointestinal discomfort, complicating early clinical suspicion.

The transmission of hantavirus is primarily zoonotic, attributable to contact with infected rodent excreta, especially in rural and agricultural settings across Canadian provinces like Manitoba, Saskatchewan, Alberta, and British Columbia. Notably, the Andes strain represents a unique epidemiologic entity, as unlike other types, it exhibits documented human-to-human transmission capability, elevating its outbreak potential and public health risk profile. Diagnostic measures for hantavirus infections leverage serological assays and polymerase chain reaction (PCR) testing, executed by specialized laboratories such as the National Microbiology Laboratory in Winnipeg, enabling timely confirmation of cases.

Treatment of hantavirus infections is predominantly supportive, given current limitations in specific antiviral therapies or vaccinations. Clinical care focuses on symptom mitigation and organ support, particularly for patients manifesting respiratory compromise or renal dysfunction. Infection control policies for hantavirus, especially when the Andes virus infection is suspected, mandate strict isolation with combined airborne, droplet, and contact precautions to curtail nosocomial transmission. Expert involvement from infectious disease specialists and immediate public health notification form critical components of outbreak management.

Turning to Ebola virus disease (EVD), this viral hemorrhagic fever has a storied history of sporadic outbreaks primarily localized in Central and West Africa since its identification in 1976. The Ebola virus genus encompasses several species pathogenic to humans, with Zaire, Sudan, and Bundibugyo being the most clinically significant. Current epidemiologic data from outbreaks, such as the Bundibugyo strain expounded in the Democratic Republic of Congo, reveal case fatality rates ranging from 30 to 50 percent. Zoonotic reservoirs are believed to be fruit bats, facilitating sporadic spillover events to human populations through direct contact or via intermediate hosts such as primates.

The clinical presentation of Ebola virus disease often includes an abrupt onset of fever exceeding 38°C, profound fatigue, myalgia, and gastrointestinal symptoms such as vomiting and diarrhea. Despite its classification as a hemorrhagic fever, only a minority of patients exhibit overt bleeding manifestations. The incubation period ranges broadly from two days to three weeks, which, coupled with nonspecific initial symptoms, underscores the difficulties faced in early detection and containment. Confirmatory diagnosis relies heavily on molecular techniques, particularly real-time PCR assays that identify viral RNA in blood or other bodily fluids.

Given the high transmissibility of Ebola virus through direct contact with infected bodily fluids — including vomitus, feces, blood, semen, and contaminated surfaces — stringent infection prevention and control measures are imperative. Health Canada and global health authorities advocate for comprehensive use of personal protective equipment (PPE), including fit-tested N95 respirators, face shields, gloves, and impermeable gowns, to safeguard healthcare providers and prevent nosocomial spread. The integration of rigorous screening protocols, careful patient assessment, and isolation of suspected or confirmed cases form the bedrock of outbreak interventions.

Advancements in the prevention and treatment of Ebola virus disease have progressed significantly over recent years. Vaccination efforts, particularly targeting the Zaire ebolavirus species, have demonstrated remarkable efficacy, with the deployment of recombinant vesicular stomatitis virus-based vaccines altering the landscape of outbreak control. Additionally, therapeutic antivirals, including monoclonal antibodies and antiviral drugs, have reduced mortality rates substantially. However, the Bundibugyo ebolavirus remains recalcitrant to these advances, lacking approved vaccines or targeted treatments, thereby necessitating reliance on supportive care to manage patients afflicted with this strain.

The clinical and virological parallels between hantavirus infections and Ebola virus disease underline the criticality of robust surveillance systems and prompt laboratory diagnostics. Both diseases exemplify zoonotic spillover phenomena, emphasizing the interface between humans, wildlife, and environmental modifications that drive emerging infectious threats. The absence of widely effective antiviral therapies and the challenges inherent to early clinical distinction from other febrile illnesses highlight ongoing gaps in medical preparedness and response.

Healthcare settings remain vulnerable points for transmission of both viruses, necessitating adherence to strict IPAC protocols. Continuous education of frontline healthcare workers concerning disease recognition and transmission mechanisms is vital for mitigating in-hospital outbreaks. Moreover, public health messaging regarding the risks associated with exposure to wildlife reservoirs and infected individuals can bolster community-level preventive practices.

In summary, the growing recognition of the public health dangers posed by hantavirus and Ebola virus infections compels an integrated approach combining epidemiologic vigilance, clinical acumen, and infection control excellence. Research and development endeavors directed toward vaccines, diagnostics, and therapeutics must persist to bridge current gaps. As global interconnectedness intensifies, the containment and management of such deadly pathogens rest on the robust collaboration of clinical practitioners, researchers, and public health authorities worldwide.

Subject of Research: People
Article Title: Hantavirus and Ebola virus disease
News Publication Date: 22-Jun-2026
Web References: https://www.cmaj.ca/lookup/doi/10.1503/cmaj.260834, https://www.cmaj.ca/lookup/doi/10.1503/cmaj.260789
References: Canadian Medical Association Journal, National Microbiology Laboratory (Winnipeg), Health Canada guidelines
Keywords: Infectious diseases, Viruses, Hantavirus, Ebola virus, Viral hemorrhagic fevers, Zoonotic diseases, Infection prevention and control, Outbreaks, Public health